Ciruelos, E. M., Montano, A., Rodriguez, C. A., Gonzalez-Flores, E., Lluch, A., Garrigos, L., . . . Casas, A. (2020). Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
Citación estilo ChicagoCiruelos, Eva M., et al. Phase III Study to Evaluate Patient's Preference of Subcutaneous Versus Intravenous Trastuzumab in HER2-positive Metastatic Breast Cancer Patients: Results From the ChangHER Study (GEICAM/2012-07). 2020.
Cita MLACiruelos, Eva M., et al. Phase III Study to Evaluate Patient's Preference of Subcutaneous Versus Intravenous Trastuzumab in HER2-positive Metastatic Breast Cancer Patients: Results From the ChangHER Study (GEICAM/2012-07). 2020.